Recent Updates — GCTK
Glucotrack, Inc. entered into a securities purchase agreement on September 24, 2026, for a registered direct offering of 169,388 shares of common stock and pre-funded warrants to purchase up to 1,350,220 additional shares. The shares were priced at $2.04 each, and the pre-funded warrants at $2.039 each, generating approximately $3.1 million in gross proceeds before fees. Dawson James Securities acted as placement agent for a fee of 8.0% of gross proceeds. Proceeds will be used to pay off existing debt, with the remainder allocated to working capital and general corporate purposes. The offering closed on September 25, 2026. Glucotrack operates in the medical device industry, focusing on the design, development, and commercialization of novel technologies for diabetes management, including an implantable continuous blood glucose monitoring system.
On September 14, 2026, Paul V. Goode resigned from the Board of Directors of Glucotrack, Inc., effective immediately. Mr. Goode cited a potential conflict of interest between the Company and its subsidiary regarding ongoing discussions about implementing duties under the merger agreement for the business combination with Lokahi Therapeutics, Inc. The Company has provided Mr. Goode an opportunity to submit a letter agreeing or disagreeing with these statements, which will be filed as an exhibit if received. Glucotrack, Inc. operates in the healthcare technology industry, developing digital health solutions.
On September 10, 2026, Glucotrack, Inc. closed a private placement of senior secured convertible promissory notes with an aggregate principal amount of $11,596,172.68. The transaction generated gross cash proceeds of $4,500,000 and involved the exchange of approximately $4,545,015 in existing debt. Notes bear 8% annual interest, mature in nine months, and convert at a price equal to the lower of $3.12 or 80% of the 15-day VWAP, subject to a floor. Investors received warrants for 4,831,739 shares exercisable at $7.50 per share for five years. The financing includes registration rights and stockholder approval requirements capped at 19.99% of outstanding shares. Glucotrack operates in the medical device industry, focusing on continuous glucose monitoring systems.